News about interchangeable Semglee (insulin glargine-yfgn) was among the most read in 2021.
Prime’s formularies will include the insulin biosimilar over the reference product Lantus beginning in January 2022.
OptumRx will favor the reference product Lantus on the Premium Formulary. The organization also released coverage information about other newly approved therapies.
AmerisourceBergen/Xcenda survey finds payers believe biosimilars provide costs savings, and they are expected to continuing contracting with manufacturers.
Patients who are part of the Walgreen’s Prescription Savings Club can receive Semglee at up to 80% off the cash price.
A reimbursement policy similar to that used for branded and generic drugs would have saved $1.6 billion from 2015 to 2019.